SDIC Securities released a research report on April 26 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the continuous development of various businesses and the steady growth of 2024Q1's performance; 2) implementing domestic and international dual cycle development strategies to promote rapid development of the medical and aesthetic business; 3) continuing to enrich the layout of the innovation pipeline, and the company is expected to enter the R&D harvest period. (Mainichi Keizai Shimbun)
国投证券4月26日发布研报称，给予华东医药（000963.SZ）买入评级。评级理由主要包括：1）各项业务持续发展，2024Q1 公司业绩稳健增长；2）践行国内国际双循环发展战略，推动医美业务快速发展；3）持续丰富创新管线布局，公司有望步入研发收获期。（每日经济新闻）
SDIC Securities released a research report on April 26 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the continuous development of various businesses and the steady growth of 2024Q
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.